[STANDARD TEXT] | [LARGE TEXT]

Clinical Research.

For over three decades Rocky Mountain Retina Consultants has been steeped in clinical research. This allows us to bring the latest treatment options, not presently commercially available, to our patients. We are able to tailor treatment regimens that are not available at other retinal surgery practices. This equates to more progressive care for our patients and physicians and staff who are focused on continually working on improving the care we provide to our patients.

Below are studies that we are currently conducting as well as studies that we have finalized.

STUDIES FOR WHICH WE ARE CURRENTLY ENROLLING:

Allergan

  • Bromonidine (“Bromo”) Posterior Segment Drug Delivery System with Retinal Detachment – 2009 – Phase II

Genentech

  • Ranibizumab (Lucentis) with Subfoveal Neovascular Age-Related Macular Degeneration (Harbor) – 2009 to present – Phase III

Regeneron

  • VEGF Trap with Neovascular Age-Related Macular Degeneration (0605) – 2007 to present – Phase III 

MacuSight

  • Sirolimus for Age-Related Macular Degeneration (Emerald) – 2009 to present – Phase II

NeoVista

  • Epi-Rad90 Ophthalmic System for Subfoveal Choroidal Neovascularizatoin with AMD (Cabernet) – 2008 to present – Pivotal
  • Epi-Rad90 Ophthalmic System for Subfoveal Choroidal Neovascularization with AMD (Meritage II) – 2009 – Pivotal

Ophthotech

  • Volociximab with Neovascular Age-Related Macular Regeneration (OPH 3000) – 2008 to present - Phase I

STUDIES FOR WHICH ENROLLMENT HAS BEEN COMPLETED:

Allergan

  • Dexamethasone Posterior Segment Drug Delivery System with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration – 2008 to present – Phase II
  • Dexamethasone Posterior Segment Drug Delivery System with Diffuse Diabetic Macular Edema – 2007 to present – Phase III
  • Dexamethasone Posterior Segment Drug Delivery System in the Treatment of Vitrectomized Subjects with Diabetic Macular Edema – 2008 to present – Phase II

MacuSight

  • Sirolimus for Diabetic Macular Edema (Diamond) – 2008 to present – Phase II

Acuity - Opko Ophthalmics

  • Bevasiranib Sodium with Exudative Age-Related Macular Degeneration (Cobalt) – 2008 to present – Phase III

Lilly

  • Protein Kinase C Inhibitor – Diabetic Retinopathy Study – 1998 to 2002 (MBBM) – Phase II/III
  • Protein Kinase C Inhibitor – Diabetic Macular Edema – 1998 to 2002 (MBBK) – Phase III
  • Protein Kinase C Inhibitor – Diabetic Retinopathy Study #2 – 2001 to 2005 – (MBCM) – Phase III
  • Protein Kinase C Inhibitor – Diabetic Macular Edema – 2004 to present – (MBDL) – Phase III
  • Protein Kinase C Inhibitor – Diabetic Retinopathy Study – 2006 to present – (MBDV) – Phase III

Genentech

  • Ranibizumab (Lucentis) in minimally Classic or Occult AMD Study (Marina) – 2003 to 2006– Phase III
  • Ranibizumab (Lucentis) in Predominantly Classic AMD Study (Anchor) – 2003 to 2006 – Phase III
  • Ranibizumab (Lucentis) with and without Classic CNV in Age-Related Macular Degeneration (Pier) – 2004 to 2007 – Phase IIIb
  • Ranibizumab (Lucentis) with Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration (Horizon) – 2005 to 2008 – Phase III Open Label
  • Ranibizumab (Lucentis) with Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration (Sailor) – 2005 to 2008 – Phase IIIb
  • Ranibizumab (Lucentis) with Macular Edema Secondary to Central Retinal Vein Occlusion (Cruise) – 2007 to 2009 – Phase III
  • Ranibizumab (Lucentis) with Macular Edema Secondary to Branch Retinal Vein Occlusion (Bravo) – 2007 to present – Phase III
  • Ranibizumab (Lucentis) with Retinal Vein Occlusion (Horizon II) – 2008 to present – Open-Label

Investigator Sponsored Trial

  • Ranibizumab (Lucentis) in Diabetic Macular Edema – 2006 to 2009 – Phase II

DRCR.net

  • A Pilot Study of Laser Photocoagulation for DME – 2003 to 2007 – Phase II
  • Intravitreal Triamcinolone and Laser Photocoagulation for Diabetic Macular Edema – 2004 to present – Phase III
  • Peribulbar Trimcinolone for Diabetic Macular Edema – 2005 to Present – Phase II
  • Evaluation of Vitrectomy for Diabetic Macular Edema – 2005 to Present – Phase II

(OSI) Eyetech

  • Pegaptanib Sodium (Macugen) in Subfoveal Neovascular Age-Related Macular Degeneration (LEVEL) – 2006 to 2008 – Phase III

Regeneron

  • VEGF Trap with Neovascular Age-Related Macular Degeneration (0508) – 2007 to 2008 – Phase II 
  • VEGF Trap with Neovascular Age-Related Macular Degeneration (0702) – 2007 to present – Open Label
  • VEGF Trap with Diabetic Macular Edema (0706) – 2008 to present – Phase II

Score

  • Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) – 2004 to Present – Phase III

CIBA Vision

  • Photodynamic Therapy Ind. Study for Macular Degeneration (VAM Study) – Phase IV